4.3 Article

Effects of TNF-α antagonist infliximab on fructose-induced metabolic syndrome in rats

期刊

HUMAN & EXPERIMENTAL TOXICOLOGY
卷 40, 期 5, 页码 801-811

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/0960327120969960

关键词

Infliximab; metabolic syndrome; TNF-α fructose; triglycerides; adiponectin

向作者/读者索取更多资源

The study found that the TNF-alpha antagonist infliximab has a certain impact on fructose-induced metabolic syndrome in rats, but it cannot completely cure all symptoms. Infliximab can reduce serum triglycerides, increase high-density lipoprotein cholesterol levels, but cannot reduce hyperglycemia, hypertension, or lower malondialdehyde levels.
Public health issues have been raised regarding fructose toxicity and its serious metabolic disorders. Deleterious effects of high fructose intake on insulin sensitivity, body weight, lipid homeostasis have been identified. The new millennium has witnessed the emergence of a modern epidemic, the metabolic syndrome (MS), in approximately 25% of the world's adult population. The current study aimed to investigate the effect of the TNF-alpha antagonist infliximab on fructose-induced MS in rats. Rats were administered fructose (10%) in drinking water for 12 weeks to induce the experimental MS model. infliximab (5 mg/kg) was injected once weekly intraperitoneally starting on the 13th week for 4 weeks. Increase in body weight, blood glucose level, serum triglycerides (TGs), adiponectin level and blood pressure were present in MS rats. They also prompted increases in serum of leptin, TNF-alpha, and malondialdehyde (MDA) levels. Treatment with infliximab did not affect body weight, hyperglycemia or hypertension, but decreased serum TGs and increased serum HDL-c levels. Infliximab also decreased adiponectin levels. Surprisingly, infliximab increased MDA above its value in the MS group. These results reflect the fact that infliximab affects the manifestations of MS in rats. Though infliximab reduced TGs, increased HDL-c levels, reversed adiponectin resistance occurred by fructose, the drug failed to combat MS-mediated hyperglycemia, hypertension, and elevated MDA above the insult.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据